Brain insulin signaling is known to control peripheral energy metabolism and regulation of mood and cognition. Dysregulation in this signaling has been tied to brain pathological disorders such as Alzheimer’s disease (AD). Previous findings have reported a strong connection between type 2 diabetes (T2D) and AD, suggesting insulin resistance as a potential risk factor for AD pathology and other forms of dementia.
Researchers from Shanghai Shyndec Pharmaceutical Co. Ltd. have detailed the discovery of novel selective serotonin reuptake inhibitor (SSRI)/5-HT1A dual targeting compounds as potential antidepressant candidates.
As many as 3.8 million people experience a traumatic brain injury (TBI) each year in the United States and it is also the strongest environmental risk factor for developing dementia, but there are no treatments to mitigate deficits from TBI.
Researchers from Suven Life Sciences Ltd. presented the discovery and preclinical characterization of a novel muscarinic acetylcholine M4 receptor positive allosteric modulator (PAM), SUVN-L1305022.
Neuropathic pain affects about 60% of patients with diabetes. The hepatocyte growth factor (HGF)/MET pathway is known to play a critical role in neurogenesis and nervous system repair; thus, its stimulation may provide neuroprotective effects, as well as reduce pain symptoms.
Bit Bio Ltd. has announced the addition to its portfolio of ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models for frontotemporal dementia (FTD), and early access to its ioGABAergic Neurons for neurological diseases, including epilepsy, schizophrenia, autism and Alzheimer's disease.
Researchers presented data from a study that aimed to assess the repair potential of acute intermittent hypoxia (AIH) treatment for compression injuries.
Investigators at the École Polytechnique Fédérale de Lausanne (EPFL; Swiss Federal Institute of Technology Lausanne) have identified a broad role for the fragile X mental retardation protein (FMRP) in suppressing antitumor immunity, they reported in the Nov. 18, 2022, issue of Science. The results could lead to new ways to boost antitumor immunity. Scientifically, they also provide new insights into the link between tumors and the nervous system.
Mutations in FMR1, the gene that codes for FMRP, cause fragile X syndrome, a neurodevelopmental syndrome that is characterized by mental retardation and autism-like symptoms.Previous work in the laboratory of Douglas Hanahan, who is the senior author of the Science paper, as well as by other teams had shown that FMRP levels were increased in several tumor types, and increased the chances that those tumors would metastasize.
Kotobuki Pharmaceutical Co. Ltd. and Astellas Pharma Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration and inflammatory disorders.
RSS
